Overview

Efficacy and Safety Study of QVA149 in COPD Patients

Status:
Completed
Trial end date:
2016-09-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Bromides
Glycopyrrolate